春节是阖家团圆的时刻，但有这么一群年轻人，忙碌得顾不上买一张回家过年的车票。他们远离家乡， 正在岗位上抓紧演练和测试，为春节假期前重要的商业航天发射做准备。仰望星空，心系卫星，这些年 轻人被亲切地称为新一代"牧星人"。 就像牧羊人管理羊群一样，"牧星人"是指从事卫星测运控工作的工程师和技术人员，他们负责监控、管 理和控制太空轨道上一颗颗卫星的运行。"我们会有自己的星链"，这已经成为年轻"牧星人"坚定的信 念。 呵护卫星太空旅程 作为时空道宇星座全球测运控中心的一线测运控工程师，来自宁夏的"90后"小伙子田劼双眼时刻紧盯监 测屏幕上卫星的运行轨迹和重要参数，一丝不苟。 对"牧星人"而言，卫星在太空中所面对的环境非常复杂，会遇到各种各样的突发情况。为确保万无一 失，时空道宇测运控团队日夜排班，对在轨卫星进行7×24小时监控。当太空中突发情况发生的时候， 地面上的"牧星人"就要立刻反应过来，并且迅速给出一个有效的解决方案。 火箭点火升空，星箭成功分离，卫星的遥测数据接收……在火箭发射的一系列过程中，田劼等"牧星 人"的角色不可或缺。 牧羊人要防范野狼偷袭羊群，"牧星人"则要时刻预防太空异物撞击卫星，因为哪怕一块看似 ...

今日提示 ·中芯国际2月11日举行2025年第四季度业绩说明会。 ·国新办2月11日举行新闻发布会，介绍2026"乐购新春"等情况。 ·松延动力Bumi-X1智脑版联名机器人2月11日正式预售。 ·*ST立方自查工作完成，公司股票2月11日开市起复牌。 上证精选 ·央行发布2025年第四季度中国货币政策执行报告，其中提出，继续实施好适度宽松的货币政策。把促 进经济稳定增长、物价合理回升作为货币政策的重要考量，根据国内外经济金融形势和金融市场运行情 况，把握好政策实施的力度、节奏和时机。灵活高效运用降准降息等多种政策工具，保持流动性充裕和 社会融资条件相对宽松，引导金融总量合理增长、信贷均衡投放，使社会融资规模、货币供应量增长同 经济增长、价格总水平预期目标相匹配。 ·2月10日，国家发展改革委等部门发布《关于加快招标投标领域人工智能推广应用的实施意见》，其中 提出，积极稳妥推进人工智能在招标投标领域的应用，改进招标投标范式，提升服务和监管的数智化水 平，为保障公共资源公平高效配置、规范招标投标市场秩序提供有力支撑。2026年底，招标文件检测、 智能辅助评标、围串标识别等重点场景在部分省市实现全覆盖应用。 ·2 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：600713 证券简称：南京医药 编号：ls2026-015 债券代码：110098 债券简称：南药转债 南京医药集团股份有限公司 2024年度第一期中期票据 2026年付息公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 为保证南京医药集团股份有限公司（以下简称"公司"）2024年度第一期中期票据（债券简称：24南京医 药MTN001，债券代码：102480759.IB）付息工作的顺利进行，现将有关事宜公告如下： 一、本期债券基本情况 ■ 二、兑付相关事宜 托管在银行间市场清算所股份有限公司的债券，其付息资金由发行人在规定时间之前划付至银行间市场 清算所股份有限公司指定的收款账户后，由银行间市场清算所股份有限公司在付息日划付至债券持有人 指定的银行账户。债券付息日如遇法定节假日，则划付资金的时间相应顺延。债券持有人资金汇划路径 变更，应在付息前将新的资金汇划路径及时通知银行间市场清算所股份有限公司。因债券持有人资金汇 划路径变更未及时通知银行间市场清算所股份有限 ...

成都红旗连锁股份有限公司 关于审计机构变更质量控制复核人的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗 漏。 成都红旗连锁股份有限公司（以下简称"公司"）分别于2025年4月18日和2025年5月15日召开第五届董事 会第二十次会议和2024年年度股东会，审议通过了《关于续聘会计师事务所的议案》，同意继续聘任立 信会计师事务所（特殊普通合伙）（以下简称"立信"）为公司2025年度审计机构和内部控制审计机构。 具体内容详见公司2025年4月19日披露的《关于聘任会计师事务所的公告》（2025-008）。 近日，公司收到立信出具的《关于变更质量控制复核人的函》，具体情况如下： 一、本次变更质量控制复核人的情况 立信作为公司2025年度财务报表及内部控制的审计机构，原指派林建昆先生作为质量控制复核人为公司 提供审计服务。因立信内部工作安排变动，林建昆先生不再担任本次审计项目的质量控制复核人，变更 后质量控制复核人为张再鸿先生。 登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：002697 证券简称：红旗连锁 公告编号：2026-003 张再鸿先生近三年 ...

Core Viewpoint - Hunan Jingfeng Pharmaceutical Co., Ltd. is undergoing a restructuring process, which has led to a significant risk of downward adjustment in its stock price due to a capital reserve increase plan that will double the total share count [2][3][4]. Group 1: Stock Price Adjustment Risk - The company plans to implement a capital reserve increase by converting its capital reserve into shares at a ratio of 1:1, resulting in an increase of total shares from 879,774,351 to 1,759,548,702 [3]. - The newly issued shares will not be distributed to existing shareholders but will be acquired by restructuring investors, with funds used for bankruptcy costs, debt repayment, and working capital [3]. - The reference price for the stock's ex-rights adjustment will be calculated based on the average price of 2.34 yuan per share, with potential adjustments depending on the stock's closing price on the registration date [4]. Group 2: Restructuring Plan Execution - The Changde Intermediate People's Court has approved the company's restructuring plan and terminated the restructuring process, moving into the execution phase [2][5]. - If the company fails to execute the restructuring plan, it may face bankruptcy, which could lead to the termination of its stock listing [5]. - The company has reported negative net profits for the years 2022, 2023, and 2024, raising concerns about its ongoing viability and compliance with stock listing rules [6].

Core Viewpoint - Zhangjiajie Tourism Group Co., Ltd. has completed its restructuring plan, leading to the removal of the delisting risk warning by the Shenzhen Stock Exchange, while continuing to implement other risk warnings due to uncertainties in its ongoing operations [2][6]. Group 1: Stock Information - The company's stock will change its abbreviation from "*ST Zhanggu" to "ST Zhangjiajie," while the stock code remains 000430 [2][3]. - The stock will be suspended for one trading day starting February 11, 2026, and will resume trading on February 12, 2026 [2][3][4]. - The daily price fluctuation limit for the stock is set at 5% [4]. Group 2: Delisting Risk Warning Removal - The delisting risk warning was implemented on November 5, 2025, following a court ruling to accept the company's restructuring application [5]. - As of February 5, 2026, the restructuring plan has been executed, and relevant reports have been issued confirming its completion [5][6]. - The Shenzhen Stock Exchange approved the removal of the delisting risk warning, effective February 12, 2026 [7]. Group 3: Ongoing Risk Warnings - The company has reported negative net profits for the last three fiscal years: -259.77 million in 2022, -239.33 million in 2023, and -582.09 million in 2024 [7]. - The audit report for 2024 indicated significant uncertainties regarding the company's ability to continue as a going concern, leading to the continuation of other risk warnings [7].

Core Viewpoint - China Resources Double Crane Pharmaceutical Co., Ltd. has announced that several of its drugs are expected to be selected in the continuation procurement organized by the National Organization for Drug Procurement, which is set to stabilize or further reduce prices while enhancing the selection power of medical institutions [1][4]. Group 1: Selected Drugs - The company participated in the continuation procurement for drugs whose agreements have expired, with several key products expected to be selected, including those that rank among the top five in revenue [1][2]. - The procurement cycle for the selected drugs will last until December 31, 2028 [1]. Group 2: Financial Impact - In 2024, the sales revenue for Valsartan Hydrochlorothiazide Tablets is projected to be 517 million yuan, accounting for 4.61% of the total revenue; for Nifedipine Controlled-Release Tablets, it is expected to be 147 million yuan, or 1.31% [3]. - For the first three quarters of 2025, the sales revenue for Valsartan Hydrochlorothiazide Tablets is estimated at 426 million yuan, representing 5.14% of total revenue; for Nifedipine Controlled-Release Tablets, it is projected at 138 million yuan, or 1.67% [3]. Group 3: Market Dynamics - The continuation procurement is expected to maintain price stability or further decrease prices, allowing medical institutions greater choice among selected suppliers, which may help ensure continuity in clinical medication and reduce risks associated with drug switching [4]. - Although the selection may lead to a decrease in overall sales revenue, it is anticipated that the company can solidify its existing market share and potentially increase its market penetration due to its brand influence and reliable supply capabilities [4].

关于2021年股权激励计划第三期限制性股票解锁暨上市公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：600587 证券简称：新华医疗 公告编号：临2026-010 山东新华医疗器械股份有限公司 重要内容提示： ● 本次股票上市类型为股权激励股份；股票认购方式为网下，上市股数为228.2513万股。 本次股票上市流通总数为228.2513万股。 ● 本次股票上市流通日期为2026年2月24日。 ● 本次解锁的限制性股票为山东新华医疗器械股份有限公司（以下简称"公司"或"新华医疗"）2021年限 制性股票激励计划第三期限制性股票。 一、股权激励计划限制性股票批准及实施情况 (一)本次股权激励计划已履行的审批程序 1、2021年11月24日，公司召开第十届董事会第十八次会议，审议通过了《关于公司〈2021年限制性股 票激励计划（草案）〉及其摘要的议案》、《关于公司〈2021年限制性股票激励计划实施考核管理办 法〉的议案》和《关于提请股东大会授权董事会办理公司202 ...

Group 1: Management Appointment - The company appointed Mr. Lou Zhangxu as the Vice General Manager, effective from the date of the board meeting approval until the end of the fourth board term [2][4] - Mr. Lou Zhangxu meets the qualifications and capabilities required for senior management positions in listed companies, with no disqualifying circumstances found [2][4] Group 2: Stock Trading Volatility - The company's stock price experienced a significant abnormal fluctuation, with a cumulative closing price increase of 100.55% over ten trading days from January 28 to February 10, 2026 [7][10] - The company's price-to-earnings ratio (TTM) was reported at 252.61, significantly higher than the industry average of 51.19, indicating a potential overvaluation risk [7][15] - The external circulation of shares is relatively small, with the controlling shareholder and their concerted actors holding 88.30% of the total shares, which may lead to irrational speculation risks [8][15] Group 3: Business Performance and Risks - The company projected a net loss for the fourth quarter of 2025, estimating a loss between 76.01 million and 26.01 million yuan, indicating potential performance volatility [8][16] - The company has invested in three films for the Spring Festival, but its investment share is low, and the market box office remains uncertain [8][17] - The AI short drama business is still in the investment and production stage, with no revenue generated yet, and its market acceptance and profitability model are uncertain [8][17]

证券代码：688187（A股） 证券简称：时代电气（A股） 公告编号：2026-005 证券代码： 3898（H股） 证券简称：时代电气（H股） ■ 本公司已分别与下述10家子公司（分公司）、保荐机构及商业银行签订《募集资金专户存储四方监管协 议》对募集资金进行监管。公司10家子公司(分公司)开设的相关专户如下： 株洲中车时代电气股份有限公司关于部分募集资金账户注销的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 株洲中车时代电气股份有限公司(以下简称"时代电气"或"公司")首次公开发行股票募集资金按照相关法 律、法规和规范性文件的规定在银行开立了募集资金专项账户。2026年2月9日公司办理完成部分募集资 金专用账户的注销手续，现将具体情况公告如下： 一、募集资金基本情况 经中国证券监督管理委员会《关于同意株洲中车时代电气股份有限公司首次公开发行股票注册的批复》 （证监许可[2021]2112号）核准，公司首次公开发行人民币普通股（A股）240,760,275股，发行价格为 人民币31.38元/股，募集资金总额为人民 ...